Cogent Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Cogent Biosciences's estimated annual revenue is currently $34.1M per year.
- Cogent Biosciences's estimated revenue per employee is $155,000
Employee Data
- Cogent Biosciences has 220 Employees.
- Cogent Biosciences grew their employee count by 18% last year.
Cogent Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO and President | Reveal Email/Phone |
2 | VP, Program Leader | Reveal Email/Phone |
3 | VP, Medicinal Chemistry | Reveal Email/Phone |
4 | VP, Pharmacology & Toxicology | Reveal Email/Phone |
5 | VP Enzymology and Structural Biology | Reveal Email/Phone |
6 | VP, CMC | Reveal Email/Phone |
7 | VP, Head Clinical Development | Reveal Email/Phone |
8 | VP, Head Clinical Development Operations | Reveal Email/Phone |
9 | VP, Head Clinical Development | Reveal Email/Phone |
10 | Director Medicinal Chemistry | Reveal Email/Phone |
Cogent Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Cogent Biosciences?
Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogent’s lead therapeutic candidate, bezuclastinib (CGT9486), is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis which can severely impact many different tissues and organs in the body. We are also studying CGT9486 to treat advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling.
keywords:N/A
N/A
Total Funding
220
Number of Employees
$34.1M
Revenue (est)
18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $50.8M | 220 | 4% | N/A |
#2 | $43.6M | 220 | 6% | N/A |
#3 | $43.8M | 221 | 1% | N/A |
#4 | $65.6M | 221 | 5% | N/A |
#5 | $15M | 222 | 16% | $2.2B |